Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $29.9 million.

  • Amphastar Pharmaceuticals' Other Non-Current Assets rose 2621.39% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 2621.39%. This contributed to the annual value of $26.0 million for FY2024, which is 31.65% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $29.9 million for Q3 2025, which was up 2621.39% from $28.1 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Other Non-Current Assets high stood at $29.9 million for Q3 2025, and its period low was $7.2 million during Q1 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Other Non-Current Assets value was $20.9 million (recorded in 2022), while the average stood at $20.5 million.
  • Within the past 5 years, the most significant YoY rise in Amphastar Pharmaceuticals' Other Non-Current Assets was 21742.86% (2021), while the steepest drop was 3556.11% (2021).
  • Amphastar Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $16.7 million in 2021, then rose by 25.15% to $20.9 million in 2022, then grew by 24.23% to $25.9 million in 2023, then increased by 0.32% to $26.0 million in 2024, then increased by 14.9% to $29.9 million in 2025.
  • Its Other Non-Current Assets stands at $29.9 million for Q3 2025, versus $28.1 million for Q2 2025 and $23.0 million for Q1 2025.